Denali Advisors’s Cabaletta Bio CABA Stock Holding History

Denali Advisors’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,300	Closed	-$295K	–	223
2024 Q1	$295K	Hold	17,300	–	–	0.09%	191
2023 Q4	$393K	Buy	+17,300	New	+$291K	0.12%	169
2023 Q2	–	Sell	-1,400	Closed	-$11.6K	–	481
2023 Q1	$11.6K	Buy	+1,400	New	+$13.1K	﹤0.01%	319

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Denali Advisors's CABA Position: Q2 2024 in Review

Denali Advisors sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 17,300 shares — an estimated $295K sold.

Denali Advisors first reported a position in CABA in Q1 2023 and held it in 3 quarters. The position peaked at $393K in Q4 2023. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

Denali Advisors reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
Denali Advisors sold 17,300 Cabaletta Bio shares in Q2 2024, an estimated $295K.
Denali Advisors first reported a position in Cabaletta Bio in Q1 2023 and held it in 3 quarters.
Denali Advisors's Cabaletta Bio position peaked at $393K in Q4 2023.
142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.